Telbolife LN 80 Tablet contains Telmisartan 80 mg + Cilnidipine 10 mg, a powerful dual-action anti-hypertensive combination used for management of moderate to severe high blood pressure.
Telmisartan blocks angiotensin II receptors to reduce vascular resistance, while Cilnidipine relaxes blood vessels by dual L- and N-type calcium channel blockade, ensuring smooth, sustained BP reduction.
Clinically, this combination is preferred for patients with uncontrolled hypertension, offering once-daily dosing, better tolerance, and improved compliance.
From a business standpoint, Telbolife LN 80 Tablet strengthens the cardiac and hypertension therapy segment, delivering strong prescription demand, repeat sales, and profitable PCD pharma franchise potential at a best price for franchise partners.